For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.


Amgen - Recent Press Releases
RSS Feeds RSS
DateTitle 
04/22/14Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 BillionPrinter Friendly Version
04/17/14Amgen Announces Webcast of 2014 First Quarter Financial ResultsPrinter Friendly Version
04/04/14Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic MelanomaPrinter Friendly Version
03/30/14Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On StatinsPrinter Friendly Version
03/29/14New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High CholesterolPrinter Friendly Version
03/26/14Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific SessionPrinter Friendly Version
03/24/14Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific SessionPrinter Friendly Version
03/17/14Amgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In Patients With Homozygous Familial HypercholesterolemiaPrinter Friendly Version
03/14/14Amgen's Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective AnalysisPrinter Friendly Version
03/12/14Amgen Names David Piacquad Senior Vice President, Business DevelopmentPrinter Friendly Version